Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "rare-diseases"

128 News Found

Need to include ASMD as a notified condition in the National Policy for rare diseases
Policy | October 20, 2023

Need to include ASMD as a notified condition in the National Policy for rare diseases

ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another


Takeda to strengthen health system for rare diseases in India
News | May 19, 2023

Takeda to strengthen health system for rare diseases in India

These initiatives aim to improve access to healthcare for rare disease patients


Sanofi reaffirms commitment to rare diseases in India
News | February 28, 2023

Sanofi reaffirms commitment to rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India


Dr Sheela Nampoothiri appointed as co-chair of ICMR's Rare Diseases expert committee
People | March 08, 2022

Dr Sheela Nampoothiri appointed as co-chair of ICMR's Rare Diseases expert committee

Dr Ratna Puri from Sir Ganga Ram Hospital, Delhi is the Chairperson of the expert committee.


Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
Drug Approval | February 07, 2026

Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease

This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease


Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
Policy | February 01, 2026

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave


Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare
Policy | February 01, 2026

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education


Biocon Biologics gets credit boost from S&P, outlook stable
News | January 30, 2026

Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’